ClinicalTrials.gg
Active, not recruitingNCT03398135COMMANDUpdated Jan 20, 2026

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

A Phase 3 interventional study of risankizumab and placebo for risankizumab in Ulcerative Colitis (UC), sponsored by AbbVie. Active, not recruiting at 426 sites in 43 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,242
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Colitis, Ulcerative by AbbVie — 6 open to participants now, 13 under way, 5 of them phase 3. Colitis, Ulcerative · AbbVie.

Enrollment
4th of 31
1,242 · median 156
Started
2018
with 2 others
Phase 3
19 of 53
1 open now
Primary completion
2028-09
later than 8 of 12 live
Registered
27th of 53
by date

Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 19 in phase 3, reaches primary completion later than 8 of the 12 other live ones, and was the 27th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

6 of the 53 studies in Colitis, Ulcerative by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Colitis, Ulcerative by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.

This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally.

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

Keywords

  • ABBV-066
  • BI 655066
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants who have completed Study M16-067 and have achieved clinical response as defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a known to risankizumab or the of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-067 that in the Investigator's judgment makes the participant unsuitable for this study.
  • Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
  • Participant is not in compliance with prior and concomitant medication requirements throughout Studies M16-067.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,242 participants (actual)

Study arms

  • Placebo comparator
    Substudy 1: Double-blind Placebo

    Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.

    Drug: placebo for risankizumab

  • Experimental
    Substudy 1: Double-blind Risankizumab Dose 1

    Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.

    Drug: risankizumab

  • Experimental
    Substudy 1: Double-blind Risankizumab Dose 2

    Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.

    Drug: risankizumab

  • Experimental
    Substudy 2: Open-label (OL) Clinical Assessment Risankizumab

    Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.

    Drug: risankizumab

  • Experimental
    Substudy 2: OL Therapeutic Drug Monitoring Risankizumab

    Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.

    Drug: risankizumab

  • Experimental
    Substudy 3: OL Extension Risankizumab

    Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.

    Drug: risankizumab

  • Experimental
    OL Continuous Treatment Extension - Dose 1

    Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 without receiving risankizumab rescue therapy in any sub-study will receive risankizumab Dose 1 administered by subcutaneous (SC) injection.

    Drug: risankizumab

  • Experimental
    OL Continuous Treatment Extension - Dose 2

    Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 and received risankizumab rescue therapy in any sub-study will receive risankizumab Dose 2 administered by subcutaneous (SC) injection.

    Drug: risankizumab

Interventions

  • subcutaneous (SC) injection

    Also known as: ABBV-066, BI 655066, SKYRIZI

  • Drugplacebo for risankizumab

    subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo Score

    Clinical remission per Adapted Mayo Score.

    Time frame: Week 52

  2. Percentage of Participants with Adverse Events (AE)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Week 300

Secondary outcomes

  1. Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement

    Endoscopic improvement per endoscopy subscore.

    Time frame: Week 52

  2. Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement

    Percentage of participants achieving histologic-endoscopic mucosal improvement.

    Time frame: Week 52

  3. Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission

    Endoscopic remission per endoscopy subscore.

    Time frame: Week 52

  4. Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with no Corticosteroid Use for 90 days

    Clinical remission per Adapted Mayo Score.

    Time frame: Week 52

  5. Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with a Clinical Remission at Week 0

    Clinical remission per Adapted Mayo Score.

    Time frame: Week 52

  6. Sub-Study 1: Percentage of Participants Achieving No Bowel Urgency

    Percentage of participants achieving no bowel urgency.

    Time frame: Week 52

  7. Sub-Study 1: Percentage of Participants Achieving No Abdominal Pain

    Percentage of participants achieving no abdominal pain.

    Time frame: Week 52

  8. Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Remission

    Percentage of participants achieving histologic-endoscopic mucosal remission per endoscopy subscore.

    Time frame: Week 52

  9. Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement in Participants with Endoscopic Improvement at Week 0

    Endoscopic improvement per endoscopy subscore.

    Time frame: Week 52

  10. Sub-Study 1: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score

    Clinical response per Adapted Mayo Score.

    Time frame: Week 52

  11. Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

    Time frame: Week 0 to Week 52

  12. Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

    The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.

    Time frame: Baseline (Week 0) to Week 52

  13. Sub-Study 1: Percentage of Participants Achieving No Nocturnal Bowel Movements

    Percentage of participants achieving no nocturnal bowel movements.

    Time frame: Week 52

  14. Sub-Study 1: Percentage of Participants Achieving No Tenesmus

    Percentage of participants achieving no tenesmus.

    Time frame: Week 52

  15. Sub-Study 1: Change in Number of Fecal Incontinence Episodes per Week

    Change in number of fecal incontinence episodes per week.

    Time frame: Baseline (Week 0) to Week 52

  16. Sub-Study 1: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms

    Change in number of days per week with sleep interrupted due to UC symptoms.

    Time frame: Baseline (Week 0) to Week 52

  17. Sub-Study 1: Percentage of Participants with Exposure Adjusted Occurrence of Ulcerative Colitis (UC) Related Hospitalization

    Participants with an exposure adjusted occurrence of UC event that results in admission to the hospital.

    Time frame: Through Week 52

07

Study locations

426 sites

Showing the first 100 of 426 sites across 43 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Panaccione R, Melmed GY, Drobne D, Kaur M, Danese S, Hisamatsu T, Kalabic J, Chen S, Cheng L, Duan WR, Shah S, Louis E. Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment. Clin Gastroenterol Hepatol. 2026 May;24(5):1424-1433. doi: 10.1016/j.cgh.2025.09.007. Epub 2025 Sep 13. PubMed 40953785 ↗
  • Reinisch W, Loftus EV Jr, Schreiber S, Rubin DT, Louis E, Hecht PM, Barrachina EM, Kalabic J, Vladea R, Sharma D, Duan WR, Zhang Y, Panaccione R. Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 4;19(4):jjaf025. doi: 10.1093/ecco-jcc/jjaf025. PubMed 40168091 ↗
  • Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M. Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11;19(1):jjaf005. doi: 10.1093/ecco-jcc/jjaf005. PubMed 39804294 ↗
  • Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. PubMed 39037800 ↗
  • Thakre N, Goebel A, Winzenborg I, Suleiman AA, D'Cunha R, Mensing S, Liu W, Pang Y. Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis. Clin Pharmacol Ther. 2024 Sep;116(3):847-857. doi: 10.1002/cpt.3330. Epub 2024 Jun 11. PubMed 38863178 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Sep 2028, 121 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 121 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 12, 2018
StartActual
Aug 28, 2018
Primary completionEst.
Sep 2028
CompletionEst.
Feb 2029
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03398135
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 12, 2018
Start date
Aug 28, 2018
Primary completion
Sep 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Jan 20, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion